SKYVEC
LIVE

Serial Number

50017135

Owner

SK Pharmteco Inc.

Attorney

Joshua M. Gerben

Filing Date

Jul 28, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SKYVEC Trademark

Serial Number: 50017135

SKYVEC is a trademark filed by SK Pharmteco Inc. on July 28, 2026. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

SK Pharmteco Inc.

12460 Akron Street, Suite 100
Rancho Cordova, CA 95742

Entity Type: 03

Trademark Details

Filing Date

July 28, 2026

Registration Date

Not Registered

Goods & Services

Custom manufacture of biopharmaceuticals; Custom manufacture of viral vectors and viral vector-based pharmaceutical products for use in gene therapy, cell therapy, and advanced therapy medicinal products; Custom manufacture of viral vectors, cell banks, viral banks, related biological materials, and pharmaceutical products for use in preclinical, clinical, and commercial gene therapy, cell therapy, vaccines, and oncolytic viral therapies; Manufacturing services for others in the field of viral vectors, cell banks, viral banks, related biological materials, and pharmaceutical products for use in preclinical, clinical, and commercial gene therapy, cell therapy, vaccines, and oncolytic viral therapies

Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceuticals for cell and gene therapies; Testing of pharmaceuticals for cell and gene therapies; Laboratory services for producing viral vectors for pharmaceutical use; Laboratory services for biomanufacturing viral vectors for pharmaceutical use; Laboratory services for biomanufacturing vaccines, oncolytic viral therapies, and advanced therapy medicinal products; Laboratory services for the production of pharmaceuticals in the nature of developing, testing, and characterizing cell banks and viral banks; Scientific and technological services, namely, development of assays, cell lines, cell banks, viral banks, analytical testing, processes, product characterization, and manufacturing, quality, and regulatory testing in the field of viral vectors, gene therapy, cell therapy, vaccines, oncolytic viral therapies, and advanced therapy medicinal products; Technological planning and consulting services in the field of viral vector development and manufacturing

Filing History

APPLICATION FILING RECEIPT MAILED
Aug 3, 2026 MAFR
APPLICATION FILING RECEIPT MAILED
Jul 29, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 28, 2026 NWOS
NEW APPLICATION ENTERED
Jul 28, 2026 NWAP